<DOC>
	<DOC>NCT00000329</DOC>
	<brief_summary>The purpose of this study is to assess the abuse liability and examine the reinforcing effects of intravenous buprenorphine and buprenorphine/naloxone combinations in buprenorphine-naloxone maintained volunteers</brief_summary>
	<brief_title>Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-1 - 4</brief_title>
	<detailed_description>Ongoing study - results not available at this time</detailed_description>
	<mesh_term>Opioid-Related Disorders</mesh_term>
	<mesh_term>Heroin Dependence</mesh_term>
	<mesh_term>Analgesics, Opioid</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<mesh_term>Buprenorphine, Naloxone Drug Combination</mesh_term>
	<mesh_term>Naloxone</mesh_term>
	<criteria>Individuals must be at least 18 yrs of age, currently opioid dependent and meet FDA criteria for narcotic maintenance treatment. Comorbid substance abuse or dependence disorders may also be present. Individuals must be healthy despite drug dependency and have a history of IV opioid use. Individuals with evidence of anti active Diagnostic and Statistical Manual of Mental Disorders (DSMIV) Axis I psychiatric disorder (e.g. psychosis, manicdepressive illness, organic psychiatric disorders), significant medical illness (e.g. liver or cardiovascular disease) or pregnant female subjects are excluded from study participation.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>drug dependence</keyword>
</DOC>